Company / Cost of Revenue
AbbVie Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$18.2B
FY2025
5-year range
$16.9B / $20.4B
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#2 of 83
Health Care
What the data says
Among 83 Health Care companies, AbbVie is in the bottom 2% for cost of revenue. Cost of Revenue has fluctuated over the past 10 years, ranging from $5.8B in FY2016 to $20.4B in FY2023.
Based on SEC 10-K filings.
$18.2B in FY2025 with a 5-year CAGR of +3.4%. Ranks 2nd among 83 companies in Health Care.
Improved from $20.4B to $18.2B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +1.5%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 83This company $18.2B Sector average $2.0B
▼
+801.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, cost of revenue increased 7.7% year-over-year.
- Ranks #2 out of 83 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.2B | +7.7% |
| FY2024 | $16.9B | -17.2% |
| FY2023 | $20.4B | +17.2% |
| FY2022 | $17.4B | -0.2% |
| FY2021 | $17.4B | +13.4% |
| FY2020 | $15.4B | +106.8% |
| FY2019 | $7.4B | -3.6% |
| FY2018 | $7.7B | +9.6% |
| FY2017 | $7.0B | +20.7% |
| FY2016 | $5.8B | +29.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026